The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
The effects of renin-angiotensin system inhibitors on mortality, cardiovascular events, and renal events in hypertensive patients with diabetes: A systematic review and meta-analysis of randomized controlled trials
Abstract
Renin-angiotensin system (RAS) inhibitors are often used as a first-line treatment for hypertensive patients with diabetes because of purported benefits, such as reno-protection. However, there is no clear evidence for the superiority of RAS inhibitors to other classes of antihypertensives for clinically important outcomes in this population. We conducted a meta-analysis to assess whether RAS inhibitors are better than other classes of antihypertensives for reducing mortality, and cardiovascular and renal events in hypertensive patients with diabetes. From June to December 2017, we searched Medline, Cochrane Library, and the database of the Japan Medical Abstracts Society (ICHUSHI) for relevant published randomized controlled trials that directly compared the effects of RAS inhibitors to other classes of antihypertensives as first-line treatments for reducing adverse outcomes among hypertensive patients with diabetes. Our predetermined outcomes included all-cause death, cardiovascular death, incidence of cardiovascular disease, and renal dysfunction. We identified 16 trials, including a total of 35,052 patients. No significant benefits for RAS inhibitors were found compared to other classes of antihypertensives for all-cause death (relative risk (RR) 0.95, 95% confidence interval (CI) 0.85-1.05, p = 0.29), cardiovascular death (RR 0.84, 95% CI 0.68-1.04, p = 0.11), incidence of cardiovascular disease (RR 0.93, 95% CI 0.84-1.03, p = 0.16), and incidence of renal dysfunction (RR 0.91, 95% CI 0.77-1.06, p = 0.22). In conclusion, RAS inhibitors are not superior to other classes of antihypertensive drugs for reducing all-cause and cardiovascular mortalities, cardiovascular events, and renal events in hypertensive patients with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The selection of medications to lower BP in persons with T2D should be guided by individual-specific considerations and may include nontraditional BP-lowering agents such as SGLT2is and GLP-1 RAs, though these drugs alone may be inadequate to control BP.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [243]
Experimental — accuracy not yet measuredIn the citing paper
“However, in a recent meta-analysis, RAS inhibitors were not superior to other classes of anti-hypertensive drugs for reducing total or CV mortality and renal events.217”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [217]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 1×
“Incidence of renal dysfunction Data on the incidence of renal dysfunction were available from six trials that included 19,671 patients and 590 events [20, 23, 25, 29, 31, 35].”
BackgroundThe ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Julius, S., Kjeldsen, S. E., Weber, M., Brunner, H. R., Ekman, S., Hansson, L., Hua, T., Laragh, J., McInnes, G. T., Mitchell, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16451-9 · Cited by 2,558
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133
Cited by
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Takuathung, M. N., Sakuludomkan, W., Khatsri, R., Dukaew, N., Kraivisitkul, N., Ahmadmusa, B., Mahakkanukrauh, C., Wangthaweesap, K., Onin, J., Srichai, S., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19148373 · Cited by 80
Hoshide, S., Kario, K., Tomitani, N., Kabutoya, T., Chia, Y. C., Park, S., Shin, J., Turana, Y., Tay, J. C., Buranakitjaroen, P., et al. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13763 · Cited by 25
Metadata
- Authors
- Kunimura, A., Himuro, N., Fujiyoshi, A., Segawa, H., Ohnishi, H., & Saitoh, S.
- Affiliations
- Shiga University of Medical Science (JP)
- Sapporo Medical University (JP)
- Corresponding author
- Kunimura, Ayako
- Venue
- Hypertension Research
- Published
- 2019-04-05
- Volume
- 42
- Issue
- 5
- Pages
- 669-680
- ISSN
- 0916-9636 (ISSN-L)
- 1348-4214
- OpenAlex
- W2925567500
- Cited by
- 17
- References
- 41
- Citations by year
- 2025: 4 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 2
- FWCI
- 0.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Hypertension Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (18H03048)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- renin-angiotensin system inhibitors, hypertension, diabetes mellitus, antihypertensive drugs, first-line antihypertensive therapy, all-cause mortality, cardiovascular mortality, cardiovascular events, renal dysfunction, renal protection
- MeSH terms
- Angiotensin-Converting Enzyme Inhibitors, Humans, Hypertension, Renin-Angiotensin System, Randomized Controlled Trials as Topic, Diabetes Complications, Renal Insufficiency, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of renin-angiotensin system inhibitors on mortality, cardiovascular events, and renal events in hypertensive patients with diabetes: A systematic review and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1038/s41440-019-0234-6
- The paper
- Kunimura, A., Himuro, N., Fujiyoshi, A., Segawa, H., Ohnishi, H., & Saitoh, S. (2019). The effects of renin-angiotensin system inhibitors on mortality, cardiovascular events, and renal events in hypertensive patients with diabetes: A systematic review and meta-analysis of randomized controlled trials. Hypertension Research. https://doi.org/10.1038/s41440-019-0234-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.